Developmental cognitive delay encompasses intellectual disabilities arising from prenatal, perinatal, or early postnatal injury or genetic factors.
Developmental cognitive delay encompasses intellectual disabilities arising from prenatal, perinatal, or early postnatal injury or genetic factors. Stem cell research in this field concentrates on neurogenic cells—progenitors capable of differentiating into neurons and supporting glial cells—and placental mesenchymal stem cells (MSCs), which secrete neuroprotective factors. The therapeutic rationale rests on replacing damaged neural tissue and reducing neuroinflammation in developing brains. Neurogenic cells, often derived from foetal sources or reprogrammed from adult tissue, may promote rewiring of neural circuits impaired by anoxia, infection, or genetic dysgenesis. Placental MSCs offer an allogeneic, non-invasive source with immunomodulatory properties. Two registered trials and one actively recruiting study are currently investigating safety and functional outcomes in paediatric populations.
| 指示性成本 · 保加利亚 (EU) | €3,000–€8,000 |
|---|---|
| 研究的主要细胞类型 | Neurogenic Cells, MSCs from Amniotic Membrane |
| 批准状态 | 研究性 |
| 注册的临床试验 (ClinicalTrials.gov) | 2 · 1 recruiting now |
For the clinic's own description, see how Stem Plus describes its Developmental Cognitive Delay programme ↗.
Two completed trials and one recruiting study form the current evidence base. Early-phase research focuses on safety in children aged 2–8 years with non-progressive intellectual disability. Published case series report modest improvements in adaptive behaviour and gross motor milestones over 6–12 months post-infusion. Functional MRI in a small cohort suggested increased activation in key learning circuits. No randomised controlled trials have been completed; comparisons are limited to historical natural history data. Effect magnitude remains unclear; blinded, sham-controlled designs are absent, limiting causal inference.
Depending on assessment, a Developmental Cognitive Delay protocol may draw on:
Treatments for developmental delay cost €4,500–7,500 per protocol in specialised neurodevelopmental centres. Neurogenic cell therapies command higher costs (€6,500–8,000) due to manufacturing complexity and regulatory oversight. Placental MSC infusions are moderately priced (€4,500–6,000). Most protocols involve 2–4 infusions over 6–12 months. No paediatric insurance scheme reimburses cell therapy for cognitive delay outside experimental frameworks. Families bear full out-of-pocket expense, creating significant access barriers in lower-income regions.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, see the Developmental Cognitive Delay cost-by-country breakdown, or compare the best countries for Developmental Cognitive Delay →
Before booking, check safety & regulation, the recovery climate, 您是否可能是候选人, and which cell type fits Developmental Cognitive Delay.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: 我是候选人吗？ · 哪种细胞类型？ · Types of clinics & best countries · 成本计算器
由 StemCellAtlas 的编辑团队进行医学审查，与Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) 合作诊所 Stem Plus（索菲亚）的，根据 ISSCR、FDA 和 EMA 指南。 Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估